The dynamics within the LABA/ICS FDC, LAMA, and biological drug classes will continue to shape the U.S. asthma market. The dominance of branded LABA/ICS FDCs (e.g., GlaxoSmithKline’s Advair, AstraZeneca’s Symbicort) will likely diminish as new generic / branded generic agents continue to launch over the next several years. In addition, the entrance of LABA/LAMA/ICS FDCs could create uptake challenges for Boehringer Ingelheim’s Spiriva. Finally, the launch of novel biologics and potentially an oral therapy will fuel competition and pricing pressure in the severe refractory segment of the asthma market. Overall, with the impending entry of multiple new branded and generic therapies, marketers of current and emerging asthma agents will be faced with increasing challenges to gain favorable formulary position and market uptake.
- Which key asthma therapies (e.g., Advair, Symbicort, GlaxoSmithKline’s Nucala, Sanofi / Regeneron’s Dupixent) receive favorable formulary placement, and how do payers manage the use and costs of these therapies?
- How do reimbursement restrictions affect physicians’ prescribing of LABA/ICS FDCs, Spiriva, and biologics to their asthma patients?
- How do payers / physicians expect current and emerging branded and generic / branded generic versions of market-leading LABA/ICS FDCs (e.g., AB-rated generics of Advair and Symbicort) to impact access / prescribing to current branded therapies?
- How do physicians anticipate using emerging biologics (e.g., Amgen / AstraZeneca’s tezepelumab), oral agents (i.e., Novartis’s fevipiprant), and LABA/LAMA/ICS FDCs (i.e., GlaxoSmithKline’s Trelegy), and how do payers expect to cover these therapies on commercial plans at various price points?
U.S. Access & Reimbursement provides in-depth insight on the impact of payer policy on prescribing behavior so that clients can build their market access strategy and optimize their brand positioning. This analysis of primary market research with physician specialists and U.S. payers helps clients stay up-to-date on restriction policies, gauge payer and prescriber attitudes toward specific therapies, identify opportunities where brands can capture patient share through market access, and maximize opportunities for emerging therapies by learning how previous brands gained favorable reimbursement or why they stumbled.
Geography: United States
Primary Research: Survey of 100 U.S. pulmonologists and allergists Survey of 30 U.S. managed care organization (MCO) pharmacy and medical directors (PDs / MDs)
Key Drugs Covered: Advair, Breo, Symbicort, Dulera, AirDuo, Wixela, Spiriva, Xolair, Nucala, Cinqair, Fasenra, Dupixent, Trelegy, tezepelumab, fevipiprant, indacaterol / mometasone, Trelegy
- Reimbursement and contracting
- Access and prescribing
- Special topics
- Opportunities and challenges for emerging therapies
- Asthma - Access & Reimbursement - Detailed, Expanded Analysis (US)
- Access & Reimbursement Asthma US August 2019
Author(s): Shubhendu Ghosh, PhD
Shubhendu Ghosh, Ph.D., is a Business Insights Analyst on the Immune and Inflammatory Disorders team at Decision Resources Group, with a primary focus on asthma.
Prior to joining DRG, Shubhendu was an Associate Editor at Nature Structural & Molecular Biology and a Copy Editor at Nature Medicine. He was also a Scientific and Developmental Editor at Nature Research Editing Service. Shubhendu received his Ph.D. in Biomedical Sciences from the University of Massachusetts Medical School after completing a B. Sc. in Microbiology from Delhi University and an M. Sc. In Biotechnology from Madurai Kamaraj University.